Finance

Lists
Why is RLMD down 2,92%?
Dive Deeper
RLMD:NASDAQ
Relmada Therapeutics Inc
3,66 US$
-2,92%
(-0,11) 1D
3,70 US$
+1,09% (+0,040)
After hours
Closed: 1 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RLMD...
Open
3,73 US$
High
3,80 US$
Low
3,65 US$
Mkt. cap
390,41 მლნ.
Avg. vol.
1,14 მლნ.
Volume
0,00
52-wk high
8,00 US$
52-wk low
1,80 US$
EPS
-0,96 US$
Beta
0,45
Shares outstanding
106,67 მლნ.
No. of employees
17
Open
3,73 US$
High
3,80 US$
Low
3,65 US$
Mkt. cap
390,41 მლნ.
Avg. vol.
1,14 მლნ.
Volume
0,00
52-wk high
8,00 US$
52-wk low
1,80 US$
EPS
-0,96 US$
Beta
0,45
Shares outstanding
106,67 მლნ.
No. of employees
17
News stories
From web sources and news partners
About Relmada Therapeutics Inc
CEO-
Employees17
Founded2004
HeadquartersCoral Gables, ფლორიდა, ამერიკის შეერთებული შტატები
SectorPharmaceutical industry
Websiterelmada.com
Analyst ratings
Based on 2 analysts giving stock ratings to RLMD in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for RLMD in the last 3 months.
Highest
Current 3,66 US$
12,00 US$ (+227,87%)
Average
12,00 US$ (+227,87%)
Lowest
12,00 US$ (+227,87%)
Analyst
Recommendation
Action
Price target
Projected
Date
Uy Ear
Mizuho Securities
Buy
Reiterated
19,00 US$
+419,1%
08/11/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
12,00 US$
+227,9%
08/10/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
12,00 US$
+227,9%
08/07/2026
Christopher Liu
Lucid Capital
Buy
Initiated
14,00 US$
+282,5%
03/02/2026
Last report
10 ნოე. 2022
Fiscal period
Q3 2022
EPS / Est. (USD)
-1,26 US$ / -1,47 US$
+14,22%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q3 2022 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
4,04 მლნ.
5,17 მლნ.
8,09 მლნ.
8,39 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,29 მლნ.
12,26 მლნ.
11,37 მლნ.
6,62 მლნ.
Operating expense
10,33 მლნ.
17,43 მლნ.
19,46 მლნ.
15,01 მლნ.
Total operating expenses
10,33 მლნ.
17,43 მლნ.
19,46 მლნ.
15,01 მლნ.
Operating income
-10,33 მლნ.
-17,43 მლნ.
-19,46 მლნ.
-15,01 მლნ.
Other non operating income
-
-
-
-
EBT including unusual items
-10,09 მლნ.
-19,87 მლნ.
-19,05 მლნ.
-12,91 მლნ.
EBT excluding unusual items
-10,08 მლნ.
-17,05 მლნ.
-18,50 მლნ.
-12,71 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-10,09 მლნ.
-19,87 მლნ.
-19,05 მლნ.
-12,91 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
247,01 ათ.
387,23 ათ.
959,76 ათ.
2,30 მლნ.
Interest expense
-
-
-
-
Net interest expenses
247,01 ათ.
387,23 ათ.
959,76 ათ.
2,30 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები